2024
Mitochondrial regulation of erythropoiesis in homeostasis and disease
Menon V, Slavinsky M, Hermine O, Ghaffari S. Mitochondrial regulation of erythropoiesis in homeostasis and disease. British Journal Of Haematology 2024, 205: 429-439. PMID: 38946206, PMCID: PMC11619715, DOI: 10.1111/bjh.19600.Peer-Reviewed Original ResearchClearance of mitochondriaComplex maturation processCell maturation processMitochondrial DNAMitochondrial participationChromatin condensationMitochondrial regulationMaturation processRetention of mitochondriaErythroid cell maturationNuclear expulsionMitochondriaErythroblast enucleationRed blood cell productionMature red blood cellsErythroid maturationRegulation of erythropoiesisCell maturationErythroid cellsHomeostasisCellsDisease conditionsRed blood cellsChromatinOrganellesHematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan A, Balmaceda N, Yacoub A, Ai J, Knight T, Ragon B, Shah N, Sanikommu S, Symanowski J, Mesa R, Grunwald M. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice. Annals Of Hematology 2024, 103: 2837-2843. PMID: 38662203, PMCID: PMC11283405, DOI: 10.1007/s00277-024-05735-7.Peer-Reviewed Original ResearchFollow-up durationPolycythemia veraThrombotic riskClinical practiceMedian follow-up durationHematocrit controlHematocrit levelsCohort study of patientsLow thrombotic riskUS Food and Drug AdministrationMonths of treatmentRisk of thrombosisStudy of patientsJanus kinase inhibitorsResponse to hydroxyureaFood and Drug AdministrationRed blood cell productionBlood cell productionCytoreductive treatmentPainful splenomegalyDose adjustmentMyeloproliferative neoplasmsPlatelet countThrombotic eventsArterial thromboses
2022
Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts
Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Ganan-Gomez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts. Blood Cancer Discovery 2022, 3: 554-567. PMID: 35926182, PMCID: PMC9894566, DOI: 10.1158/2643-3230.bcd-21-0220.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeRed blood cell productionSF3B1-mutant myelodysplastic syndromesMDS-RSRinged sideroblastsBlood cell productionSF3B1 mutationsDevelopment of therapiesCell productionRed blood cellsRed blood cell maturationHematologic responseSignificant anemiaTransfusion dependencyIron overloadMDS subtypesElderly populationSide effectsBone marrowCell maturationIssue featurePatientsBlood cellsErythroid precursorsBlood cell maturation
2020
Severe megaloblastic anemia: Vitamin deficiency and other causes
Socha DS, DeSouza SI, Flagg A, Sekeres M, Rogers HJ. Severe megaloblastic anemia: Vitamin deficiency and other causes. Cleveland Clinic Journal Of Medicine 2020, 87: 153-164. PMID: 32127439, DOI: 10.3949/ccjm.87a.19072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMegaloblastic anemiaRed blood cell productionVitamin supplementationLaboratory findingsVitamin deficiencyBlood cell productionIntramedullary hemolysisCobalamin deficiencyMacrocytic anemiaCommon causeCase of deficiencySevere casesNeoplastic diseaseCharacteristic morphologicFolate deficiencyUnderlying causeAnemiaCell productionCauseDeficiencyDiscontinuationMedicationsTherapyDiseaseSupplementation
1996
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
Cruz D, Perazella M, Abu-Alfa A, Mahnensmith R. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? American Journal Of Kidney Diseases 1996, 28: 535-540. PMID: 8840943, DOI: 10.1016/s0272-6386(96)90464-3.Peer-Reviewed Original ResearchConceptsChronic hemodialysis patientsEnzyme inhibitor therapyACE inhibitorsHemodialysis patientsInhibitor therapySevere anemiaGroup 2Group 1End-stage renal diseaseExacerbation of anemiaSuppression of angiotensinChronic renal failureCongestive heart failureTherapy of anemiaBone marrow responseSignificant differencesRed blood cell productionRecombinant human EpoRHuEPO responseChronic hemodialysisErythropoietin resistanceRenal transplantationBaseline characteristicsHospital daysRenal failure
1995
Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels
Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia M. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. American Journal Of Kidney Diseases 1995, 26: 495-500. PMID: 7645558, DOI: 10.1016/0272-6386(95)90496-4.Peer-Reviewed Original ResearchConceptsRed blood cell massBlood cell massErythropoietin levelsEnalapril therapyPosttransplant erythrocytosisHemoglobin concentrationMU/mLElevated red blood cell massMean reticulocyte countRed blood cell destructionRenal transplant patientsMean pretreatment valuePlasma volume contractionMean levelsMean hemoglobin concentrationBlood cell destructionRed blood cell productionMechanism of actionEnalapril treatmentTransplant patientsMean hematocritPretreatment valuesBlood cell productionReticulocyte countEnzyme inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply